Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 4/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29995937 | 1.00 | ATM (0.50) | ATMCCR3SMN1; SMN2KDM4EPRMT3 | |
| SCHEMBL29996110 | 0.93 | CCR3 (0.46) | ATMCCR3KDM4EMAPTALDH1A1 | |
| SCHEMBL21063195 | 0.93 | CCR3 (0.46) | ATMCCR3KDM4EMAPTALDH1A1 | |
| SCHEMBL21062956 | 0.89 | ALDH1A1 (0.41) | KDM4EMAPTALDH1A1GAAL3MBTL1 | |
| SCHEMBL29995953 | 0.89 | ALDH1A1 (0.41) | KDM4EMAPTALDH1A1GAAL3MBTL1 | |
| SCHEMBL21063223 | 0.87 | CCR3 (0.48) | CCR3PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL29996058 | 0.85 | NOS3 (0.41) | SIGMAR1HTR1A | |
| SCHEMBL21063005 | 0.85 | NOS3 (0.41) | SIGMAR1HTR1A | |
| SCHEMBL21063255 | 0.85 | ADORA2A (0.45) | ATMSMN1; SMN2KDM4EMAPTKMT2A | |
| SCHEMBL21063102 | 0.85 | DRD4 (0.38) | ATMCCR3KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723754-B1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20210053973-A1 | IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2021-02-25 | — | — | US | claimed |
| EP-3723754-A1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2020-10-21 | — | — | EP | claimed |
| WO-2019118313-A1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | WO | claimed |
| EP-3723754-B1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-11498923-B2 | Substituted imidazo[1,2-c]quinazolines as A2A antagonists | MERCK SHARP & DOHME LLC (US) | 2022-11-15 | — | — | US | disclosed |
| US-11498923-B2 | Substituted imidazo[1,2-c]quinazolines as A2A antagonists | MERCK SHARP & DOHME LLC (US) | 2022-11-15 | — | — | US | disclosed |
| US-20210053973-A1 | IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210053973-A1 | IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2021-02-25 | — | — | US | disclosed |
| EP-3723754-A1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118313-A1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | WO | disclosed |
| WO-2019118313-A1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498923-B2 | Substituted imidazo[1,2-c]quinazolines as A2A antagonists | ADORA2A, ADORA3, ADORA1 | ATM 2408/4885CCR3 1904/4885SMN1; SMN2 418/4885 |
| US-20210053973-A1 | IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA3, ADORA1 | ATM 2251/4885CCR3 2213/4885SMN1; SMN2 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.